Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Updates in Juvenile Dermatomyositis: Pathogenesis & Patient Care

Jason Liebowitz, MD, FACR  |  Issue: September 2021  |  July 17, 2021

Consider the diagnosis of clinically amyopathic dermatomyositis in patients who have had at least six months of skin rashes, such as a heliotrope rash, without obvious weakness, said Dr. Reed. Of these patients, about 25% will progress to juvenile dermatomyositis.1

The presence of myositis-specific antibodies can help clinicians screen for and predict specific manifestations of particular myositis phenotypes that may occur over time in patients’ lives. Examples:

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  • Antibodies to nuclear matrix protein-2 (NXP2) correlate with calcinosis, contractures and significant skin involvement.
  • Antibodies to transcriptional intermediary factor-1γ (TIF-1γ) often predict severe cutaneous involvement, generalized lipodystrophy, photoerythema and psoriasiform lesions.
  • Antibodies to TIF-1γ in adults are associated with malignancy, but this association is not seen in children.
  • Antibodies to melanoma differentiation-associated gene 5 (MDA5) are associated with amyopathic disease, ulcerations of the skin and interstitial lung disease, which can be rapidly progressive.

Whenever possible, rheumatologists should seek to identify which myositis-specific antibodies are present in their patient and use this information to be proactive in delivering care to these patients, said Dr. Reed.

Treatment

No treatments have been approved by the U.S. Food & Drug Administration (FDA) for JDM. Many empiric treatments, which are based on expert recommendations and consensus treatment protocols, have significant side effects. But Dr. Kim said a few trials do exist on which to base treatment recommendations.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In a retrospective study of 60 patients with JDM who had received at least three months of treatment with a tumor necrosis factor (TNF) α inhibitor (i.e., infliximab or adalimumab), patients experienced improvements from baseline with respect to skin disease as measured by the modified skin disease activity score, physician’s global disease assessment and muscle disease as measured by the Childhood Myositis Assessment Scale (CMAS) and Manual Muscle Testing (MMT8).6

In a different retrospective study of 56 patients with JDM who received treatment with cyclophosphamide using the EuroLupus dosing protocol, patients experienced reductions in skin disease, global disease and muscle disease at months 6, 12 and 24, compared with their condition at the start of treatment.7

Finally, Dr. Kim presented intriguing evidence that Janus kinase inhibitors (jakinibs) may effectively treat JDM by blocking the interferon signaling pathway.

With respect to medications, corticosteroids are recognized as an essential component of treatment for patients with JDM. Yet no widespread consensus exists on the exact dose and duration of corticosteroids to use in these patients. Similarly, questions remain as to which immunosuppressive agents, such as methotrexate, mycophenolate mofetil or rituximab, should be employed, as well as the sequence in which to try such therapies.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsMeeting Reports Tagged with:juvenile dermatomyositisPathogenesisPediatric RheumatologyPediatric Rheumatology SymposiumPRSYM

Related Articles

    Inflammatory Myopathies in Children

    July 10, 2012

    Treatment options and recent research for juvenile dermatomyositis.

    New Tools for Myositis Diagnosis, Classification & Management

    April 15, 2019

    CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…

    Oksana Kuzmina/shutterstock.comx

    Environmental Factors in Pediatric Systemic Autoimmune Diseases

    March 20, 2017

    Systemic autoimmune diseases are thought to result from immune dysregulation in genetically susceptible individuals who were exposed to environmental risk factors. Many studies have identified genetic risk factors for these diseases, but concordance rates among monozygotic twins are 25–40%, suggesting that nonheritable environmental factors play a more prominent role.1,2 Through carefully conducted epidemiologic and other…

    Autoantibodies in Autoimmune Myopathy

    Autoantibodies in Autoimmune Myopathy

    September 18, 2017

    In recent years, scientists and clinicians have learned a great deal about autoantibodies occurring in idiopathic inflammatory myopathies (IIMs). These new discoveries have reshaped our understanding of distinct clinical pheno­types in IIMs. Scientists continue to learn more about how these auto­antibodies shape pathophysiology, diagnosis, disease monitoring, prognosis and optimum treatment. Moving forward, these autoantibodies will…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences